Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / ModernaTX, Inc.

Clinicaltrial registered5 Nov 2026

ModernaTX, Inc.

5 Nov 2026: Trial registered · A Study to Investigate the Safety and Immunogenicity of mRNA-1469 in African Participants 1 to 65 Years of Age. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
5 Nov 2026
Title
A Study to Investigate the Safety and Immunogenicity of mRNA-1469 in African Participants 1 to 65 Years of Age
Conditions
Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Uganda
Country
Uganda
Reference
NCT07919197
Location
Uganda
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at ModernaTX, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for ModernaTX, Inc. in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.